Perrigo (PRGO) Lags Q2 Earnings and Revenue Estimates

Core Viewpoint - Perrigo reported quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.59 per share, but showing an increase from $0.53 per share a year ago, indicating a -3.39% earnings surprise [1] - The company posted revenues of $1.06 billion for the quarter, missing the Zacks Consensus Estimate by 2.63%, and a slight decrease from $1.07 billion year-over-year [2] Financial Performance - Over the last four quarters, Perrigo has surpassed consensus EPS estimates two times [2] - The company has not been able to beat consensus revenue estimates over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $1.12 billion, and for the current fiscal year, it is $3.04 on revenues of $4.44 billion [7] Stock Performance and Outlook - Perrigo shares have increased by approximately 3.5% since the beginning of the year, compared to the S&P 500's gain of 7.1% [3] - The company's earnings outlook and management's commentary on the earnings call will be crucial for future stock price movements [3][4] - The estimate revisions trend for Perrigo was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which Perrigo belongs, is currently in the bottom 41% of over 250 Zacks industries, which may impact stock performance [8] - Another company in the same industry, Cresco Labs Inc., is expected to report a quarterly loss of $0.04 per share, with revenues projected to decline by 11.1% year-over-year [9]